DEVELOPMENT AND ASSESSMENT OF POLYMERIC NANOPARTICLE-BASED CAPSULE COMPOSITES FOR PEPTIC ULCER TREATMENT

Abstract

The study focused on the formulation and evaluation of polymeric nanoparticle capsule composites, using a combination of natural polymer chitosan and synthetic polymer methylcellulose, to improve drug delivery systems. These polymers were chosen for their biocompatibility and ability to enhance drug stability and release. Among various formulations tested, formulation F2 emerged as the most optimized, demonstrating excellent performance across key parameters. F2 displayed the smallest particle size (78.04 nm), which enhances cellular uptake and increases the surface area available for drug interaction. The formulation also showed the highest entrapment efficiency (97.93%) and excellent drug content (98.84%), ensuring a high payload and effective drug delivery. The strong zeta potential (53.4 mV) further confirmed the formulation’s stability, minimizing aggregation and enhancing dispersion in biological systems. In vitro drug release studies showed that F2 had a remarkable release rate of 98.45% over 6 hours, outperforming all other formulations. This rapid drug release is beneficial for medications requiring fast absorption or quick therapeutic effects. Additionally, when compared to traditional lansoprazole capsules, F2 showed superior drug release, suggesting potential for better therapeutic outcomes. Animal studies also supported F2’s efficacy, as it effectively treated stomach inflammation and ulcerative conditions, showing superior therapeutic performance compared to other formulations. These results indicate that F2 is a promising candidate for clinical applications in treating gastric disorders, offering enhanced drug delivery, optimized release characteristics, and improved therapeutic effects, making it an ideal choice for future use.